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Abstract
This case study focuses on the effectiveness of the recent regulations imposed upon
Massachusetts’s prescription monitoring program. Abuse and/or misuse of prescription opioids is
becoming increasingly problematic within the United States and as a result many policy makers
are looking for ways to combat the problem. In Massachusetts, the OxyContin and Heroin
Commission was established to investigate the impact of both OxyContin and heroin on the state.
The Commission delivered recommendations that eventually led the state legislature to make
changes to Massachusetts’s prescription monitoring program. This study targeted five major
stakeholder groups and asked a series of questions through interviews and surveys. The research
question was as follows: do major stakeholders see the recent regulations imposed upon the
states prescription monitoring program as being effective in helping to combat abuse and misuse
of prescription opioids in Massachusetts? Findings produced two main themes: 1) stakeholders
believe prescription monitoring programs are successful in combating prescription drug abuse
and/or misuse and, 2) there is an overwhelmingly negative attitude towards Massachusetts
program design. Recommendations include determining how widespread the feelings of
negativity and general lack of knowledge are felt across the Commonwealth, to educate users on
the benefits of the program and encourage routine use, and to engage the state’s licensing board.
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A case study of the regulation imposed upon
Massachusetts’s prescription monitoring program
Introduction
Historically, drug addiction, abuse and misuse has been a sensitive subject that many
people tend to shy away from acknowledging or even discussing in social settings. In reality, a
large number of individuals, as well as their families, struggle with the horrors of drug addiction,
abuse and/or misuse on a daily basis. According to the United States Food and Drug
Administration (FDA) more than 16,000 lives are lost each year due to opioid-related overdoses
(2014). In many cases addicts, abusers, misusers and their families struggle in silence because
they fear how society will judge them. However, in recent years the misuse and abuse of
prescription opioid drugs has become increasingly more prevalent and problematic within the
United States (National Institute on Drug Abuse, 2011). The number of unintentional opioid
related overdoses increased from approximately three thousand in 1999 to twelve thousand in
2008 (National Institute on Drug Abuse, 2011). As a result, the issue of prescription drug abuse
and/or misuse is now affecting a significantly wider range of people than ever before. There are a
number of reasons why the misuse and abuse of prescription opioid drugs has become
problematic, including but not limited to the following: 1) these types of drugs are now more
readily available than ever before, 2) many people do not realize how addictive the drugs can be,
3) there is a common misconception that they are “safer” than other drugs because a doctor
prescribes them, and 4) they give the same recreational high as heroin yet come with less of a
social stigma (National Institute on Drug Abuse, 2011).
OxyContin is one prescription opioid that has been receiving significant attention in
recent years for being highly addictive and frequently abused and/or misused. Misuse is defined
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as taking a prescription medication for a purpose or in a manner other than it was prescribed, or
taking a prescription medication that was not prescribed to that particular person. In contrast,
“abuse” of a prescription drug is when a person takes a prescription drug to achieve a euphoric
high or for recreational purposes alone (Federal Drug Administration, 2010). OxyContin is a
prescription pain pill that offers an extended release of oxycodone hydrochloride to help
individuals with moderate to severe pain that requires relief for several days or more (Cicero,
Inciardi and Munoz, 2005). Significant opioid misuse and abuse can be linked to the market
introduction of OxyContin in 1996, mainly because of its addictive tendencies and availability.
In fact, opioid addiction rates in Massachusetts increased by 950% between 1996 and 2006
(Massachusetts OxyContin and Heroin Commission, 2009).
As a result of prescription opioid misuse and abuse becoming increasingly problematic,
many states have imposed regulations upon the prescription drug industry at large (Garcia,
2013). The majority of these regulations are intended to combat the misuse and abuse of such
drugs by placing more accountability and obligation upon those who are not only prescribing the
drugs, but also those who dispense them. In Massachusetts, the OxyContin and Heroin
Commission was created under Chapter 302 Section 56 of the Acts of 2008 by the State
Legislature to investigate the impact of both OxyContin and heroin on the state and in turn make
policy recommendations to help combat the issue.
The recommendations made by the OxyContin and Heroin Commission aim to ensure
that doctors and pharmacists are held to a higher standard, and require them to better manage and
monitor the prescriptions they prescribe or dispense. The regulations that have been imposed are
relatively recent and the long term effects have yet to be determined. Therefore, this study will
focus on the short term effectiveness of the regulations pertaining to the states Prescription
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Monitoring Program. Specifically, this case study will determine how the recent regulations are
affecting several stakeholders and determine whether those stakeholders see the regulations as
being effective and/or helpful in combating the misuse and abuse of prescription opioid drugs in
Massachusetts.
The research question is as follows: do major stakeholders see the recent regulations
imposed upon the states prescription monitoring program as being effective in helping to combat
abuse and misuse of prescription opioids in Massachusetts? In addition, the larger question of
how major stakeholders have been impacted as a result of the recent regulations will also be
addressed.
This case study will provide information on how the industry in Massachusetts has
changed as a result of the regulations. In addition, the case study will contribute to overall
research on the topic by potentially uncovering adverse effects or unintended consequences of
the regulations that should be considered when developing further policy recommendations. At
this time there is a lack of research on how these regulations function in terms of success and/or
failure and how they affect different stakeholders. This case study will examine best practice
standards for prescription monitoring programs and help to determine if the recent regulations
surrounding Massachusetts’ state program are functioning as intended and in line with best
practice standards.
History/Context
OxyContin is readily available for several reasons. In many cases the drug is legally
distributed to pharmacies and then makes its way to the black market through diversion, fraud,
false prescriptions, and doctor shopping (Massachusetts OxyContin and Heroin Commission,
2009). Diversion occurs when a prescription drug is dispensed or distributed in a manner other
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than its intended purpose. Doctor shopping is when abusers target doctors that are known to be
careless or sympathetic when prescribing or when a person visits multiple doctors and
pharmacies in order to obtain multiples of the same prescription. In addition, some patients will
sell their prescriptions for profit. The profitability is significant and serves as a motivator for
diversion because OxyContin can be sold for up to $100 per tablet on the black market. Abusers
of OxyContin are known to crush the pill in order to destroy the time-release feature, and either
snort, inject or chew the tablet in order to achieve a euphoric high (Massachusetts OxyContin
and Heroin Commission, 2009). The high that is associated with destroying the time-release
feature is comparable to the high that is associated with heroin, making these two drugs virtually
interchangeable. Studies have shown that many OxyContin abusers will eventually turn to heroin
because it is cheaper and even more readily available than OxyContin (Massachusetts OxyContin
and Heroin Commission, 2009).
Accounts of prescription drug abuse leading to heroin use are becoming more and more
prevalent in today’s news stories. According to a Boston Globe article dated February 18, 2014,
the City of Taunton witnessed 64 incidents related to heroin in a month and a half with 5 of those
incidents resulting in death (Sampson and Anderson, 2014). The article also states that’s
advocates at the community meeting stressed that majority of users do not start off with heroin,
but rather transition to the drug after first being prescribed opiates. In addition, a report on
February 9, 2014 in the Vermont Valley News, law enforcement officials stated that they
encounter heroin on a daily basis and most of it is reportedly coming from Massachusetts
(Fleisher, 2014). As a result of such instances and the growing number of opiate related
overdoses and deaths, Governor Deval Patrick recently declared a public health emergency in the
state of Massachusetts (MacQuarrie, 2014).
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Research shows that prescription drug abuse has increasingly become an issue for a wide
range of people varying in age and background (Grau, et. al, 2007). Due to the fact that this issue
is reaching a multitude of different people, prescription painkiller abuser is now considered to
have reached epidemic proportions (Garcia, 2013). As a result, prescription drug abuse is no
longer perceived as an individual struggle but rather a social issue that warrants public
consideration. The Massachusetts OxyContin and Heroin Commission (2009) stated that opiate
addiction within the Commonwealth has reached epidemic proportions larger than was seen with
the flu pandemic, which constitutes this as a serious public health issue that warrants careful
consideration and attention.
The Massachusetts OxyContin and Heroin Commission was established in the 2007-2008
legislative session to investigate the issues surrounding OxyContin, heroin and other opioid
abuse and misuse within the Commonwealth. The Commission was comprised of legislative and
gubernatorial appointments who examined various policies surrounding substance abuse, the
total direct and indirect cost of said policies, how opioid drugs are making their way to the streets
and how families across the Commonwealth are being impacted by the issue. In turn they were
expected to make policy recommendations that would help combat the growing opioid epidemic.
The Commission delivered recommendations relating to the following policy areas: 1)
prevention and education, 2) distribution, dispensing and handling, 3) prescribing and
monitoring, and 4) expansion of access to treatment services (Massachusetts OxyContin and
Heroin Commission, 2009).
The Massachusetts OxyContin and Heroin Commission was established during a time
when the Commonwealth was facing a serious problem. Not only had OxyContin abuse and/or
misuse reached epidemic proportions but the state budget was also greatly impacted trying to
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combat the issue. In 2005, the total cost of substance abuse and addiction to the Commonwealth
amounted to 21.8% of the state’s total budget. In addition, the state paid nearly $200 million in
emergency room costs related to opioid related overdoses (Massachusetts OxyContin and Heroin
Commission, 2009). Furthermore, in 2002, Boston had the highest rate of OxyContin related
emergency room visits in the country (Massachusetts OxyContin and Heroin Commission,
2009).
Despite the fact that over $4.5 billion was spent on substance abuse and addiction,
Massachusetts was ranked in the lower 50% of states in terms of total money spent on
prevention, treatment and research (Massachusetts OxyContin and Heroin Commission, 2009).
Only 2% of the $4.5 billion, or $66 million, was spent on prevention, treatment and research
(Massachusetts OxyContin and Heroin Commission, 2009). The report presented to the
legislative body of the Massachusetts State House in November of 2009 included 20 policy
recommendations to update existing laws and create new laws pertaining to prescribing and
dispensing substances that are controlled by the federal government and subject to regulation by
the Drug Enforcement Agency (Massachusetts OxyContin and Heroin Commission, 2009).
The Commission revealed that the state’s prescription monitoring program was failing to
be an effective resource in combating the opiate epidemic. As a result, the commission made
several recommendations to improve the state’s prescription monitoring programs in hopes of it
being used as an effective preventative tool. The Commission stated that although completely
stopping misuse and/or abuse of prescription drugs is highly unlikely, reducing reckless or
fraudulent distribution of the drugs is a realistic goal. Therefore, they concluded that one of the
most efficient ways to stop fraud and limit the availability of opioid prescriptions is to have an
active and useful prescription monitoring program.
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As a result of the recommendations made by the Commission, the Massachusetts State
Legislature eventually adopted legislation to reform state regulations. An Act Relative to
Prescription Drug Diversion, Abuse and Addiction was adopted in August of 2012 and became
Chapter 244 of the Acts of 2012. The legislation most notably made changes to Massachusetts’
prescription monitoring program. Prescription monitoring programs maintain statewide
databases that contain information regarding prescriptions that have been dispensed containing
controlled substances. According to the Massachusetts Department of Public Health (2014) the
goal of prescription monitoring programs are to promote safe prescribing and dispensing and to
assist in addressing prescription drug misuse and abuse.
Under the new legislation, the Department of Public Health is charged with ensuring that
all prescribers who are licensed to prescribe a controlled substance are automatically enrolled in
the state’s prescription monitoring program upon license renewal. In addition, it is now
mandatory for prescribers to check the database for all new patients, which was not required in
years past. In addition, the Act grants expanded database access to pharmacists within the
Commonwealth. Practitioners and pharmacists in Massachusetts are required to fill out an
enrollment form in order to be granted access, which can be viewed in Appendices A and B.
The Commission concluded that their recommendations surrounding prescription
monitoring were the most promising of all the recommendations. They stated that resuscitating
and improving the states program would help combat the opioid epidemic as well as save money
for the Commonwealth. The recommendations surrounding the states prescription monitoring
program were intended to make the program more accessible to non-governmental stakeholders
such as pharmacists and prescribers and ensure that real time data is available and can flow in a
non-restrictive and streamlined fashion.
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Literature Review
Overview
Because prescription drug abuse and misuse has only been considered a social issue in
the recent past, there has not been extensive research on the long term effects of regulating
prescribing and dispensing of pharmaceuticals. However, significant research has focused on the
regulations and how they affect different stakeholders in the short term. Policy makers have been
charged with creating regulations that limit prescription drug diversion but at the same time do
not interfere with adequate treatment of pain. In many cases, satisfying both objectives can be a
challenge. According to Fishman et al. (2004), state and national organizations are considering
under treatment of pain as a serious public health problem, underscoring the need for finding a
balance between properly regulating prescribing and dispensing prescription drugs and proper
treatment of pain. Many scholars believe that prescription monitoring programs promote more
informed prescribing without deterring practitioners from prescribing controlled substances
when needed (Perrone and Nelson, 2012). The National Alliance for Model State Drug Laws
specifies that prescription monitoring programs are intended to do just that; support legitimate
medical use of controlled substances while limiting diversion, misuse and abuse (Gugelmann and
Perrone, 2011).
Many researchers support the use of prescription monitoring programs. Prescription
monitoring programs were first established in 1989, with only 9 states participating in some
capacity. By 2013, 49 out of 50 states had adopted some type of prescription monitoring program
with the intention of better identifying inappropriate prescribers, their dispensing patterns, and to
detect drug seekers and monitor behaviors (Garcia, 2013). Paulozzi et al. (2011) state that with
proper program design, prescription monitoring programs have proven to be successful in
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reducing misuse and abuse of prescription drugs. Garcia (2013) supports this claim and stresses
the need for proper program design in order to reduce doctor shopping along with change
prescribing behaviors. A survey of substantial literature regarding prescription monitoring
programs produced two major themes relating to how an ideal program is run: 1) real time data
and 2) access.
Real Time Data
In the pre-internet era, programs that required data input and sharing of data, such
as prescription monitoring programs, were not very effective. According to Fishman et al.
(2004), non-computerized monitoring programs actually had a negative impact on areas of
legitimate medical care because pharmacists were prescribing based on outdated information.
However, due to the development of the Internet, prescription monitoring programs are no longer
facing limiting factors such as reporting with paper documentation, and the voluntary nature of
reporting (Perrone and Nelson, 2012). Presently collecting and sharing real time data is not only
a possibility, but it is easier than ever before with the help of electronic data transmission
systems (Fishman et al., 2004). According to the Massachusetts Department of Public Health
(2014) Massachusetts’s prescription monitoring program is in fact a computer-based, Electronic
Data Transfer system (EDT).
Clark et al. (2012) state that real time data that is constantly available is critical for the
success of a prescription monitoring program, particularly in cases where dispensing occurs at 24
hour facilities. Therefore, it is critical to ensure that it is not burdensome or time consuming for
pharmacists to upload information to the prescription monitoring program and encourage them to
do so in a timely manner (Perrone and Nelson, 2012). Clark et al (2012) state that ideally,
prescription monitoring programs should collect data within minutes of dispensing. According to
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the Massachusetts Department of Public Health (2014) pharmacists are required to input data
into the state’s prescription monitoring program on a weekly basis but they are not mandated to
consult the database before dispensing a prescription. In addition, the regulations encourage
pharmacists to use professional judgment in deciding when to consult the database before
dispensing (Ryle, 2013).
Gugelmann and Perrone (2011), discuss a study conducted in 2010 that supports the need
for information that is updated in real time. The study looked at 179 clinical records that were
reviewed by practitioners in Ohio’s prescription monitoring program database. Having real time
data available resulted in the practitioners changing their prescription practices in 41% of their
interactions with patients.
Many believe that the quality of a patient’s care can be significantly improved if those
who are responsible for the patient have access to up-to-date, live information. According to
Brushwood (2003), effective prescription monitoring programs provide feedback regarding a
patient’s history in a timely manner to physicians and pharmacists who are responsible for that
patient. Perrone and Nelson (2012) argue that in order for a prescription monitoring program to
be most valuable in clinical practice, it must be current. According to Clark et al. (2012), varying
intervals of data collection compromise the utility of the data and significantly limits the success
of the prescription drug monitoring program. In Massachusetts, practitioners are required to
consult the database only when treating a new patient (Department of Public Health, 2014). This
could potentially be problematic because physicians may have current patients that are abusers
and or/misusers which would go undetected. Whereas, states such as Rhode Island and
Connecticut require practitioners to consult the database every time they prescribe a controlled
substance, in an attempt to avoid such misdetections (Rhode Island Department of Health, 2014;
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Connecticut Department of Consumer Protection, 2014).
Furthermore, research shows that effective prescription monitoring programs must be
comprehensive and accurate in data reporting. Brushwood (2003) describes a comprehensive
program as one that requires the reporting and aggregation of data of all controlled substances
that are dispensed versus only schedule II drugs. The United States Drug Enforcement
Administration classifies drugs, substances, and certain chemicals used to make drugs into five
categories or schedules ranging from I-V based on the drug’s acceptable medical use and the
drug’s abuse or dependency potential. Schedule I drugs have the highest potential for abuse
and/or dependence whereas Schedule V drugs have the least potential for abuse and/or
dependence (United States Drug Enforcement Administration, 2014). Brushwood (2003) goes on
to state that not having a comprehensive program could result in not catching shifts in drug
seeking behaviors. In Massachusetts, community pharmacies, hospital outpatient and clinical
pharmacies as well as out of state mail order pharmacies that service patients in Massachusetts
are required to report to the states prescription monitoring program (Massachusetts Department
of Public Health, 2014). In addition, Massachusetts’s prescription monitoring program reports on
schedule II-V drugs and includes extensive information such as fill date, quantity, prescriber,
dispensing pharmacy and insurance information (Ryle, 2013).
Research also shows that it is important to be comprehensive regarding the different
types of pharmacies that are available (Brushwood, 2003). For example, mail order, internet
pharmacies, hospital and retail pharmacies should all be required to report to the prescription
monitoring program within their respective patient’s state. Perrone and Nelson (2012) claim that
in order to truly be effective all monitoring programs should have comprehensive information on
the prescriber, the patient, the pharmacy, generic name of the drug, the dosage prescribed,
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number of units dispensed, and the dates of both prescribing and dispensing. In addition,
Brushwood (2003) argues that maintaining accuracy when inputting and using patient data is
critical for a prescription monitoring program to be effective. If the data that is being reviewed is
not accurate or even outdated then the purpose of the program is lost.
Access
The second major component to running a successful prescription monitoring program is
allowing user-friendly and standardized access for a variety of stakeholders. Interstate access is a
major hindrance for the effectiveness of prescription monitoring programs and failure to share
data amongst states can lower the effectiveness of prescription monitoring programs. Since each
state is charged with implementing and maintaining their own program, prescription monitoring
programs vary greatly from state to state (Garcia, 2013). Such differences include the types of
drugs that are reported, when prescribers are required to consult the database, how often
dispensers must report data to the system, what stakeholders have access to the data, and whether
the data can be shared with other states or not (Garcia, 2013). The chart below (figure 1) shows
how the Massachusetts’s prescription monitoring program compares to both Rhode Island and
Connecticut’s prescription monitoring programs in terms of who has access to the database, how
often it is updated, when prescribers are required to consult the database, what drugs are
monitored and whether or not the state shares information with other states.
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Who has
access

MA

RI

CT

Practicioners,
Pharmacists,
Delegates,
Law
Enforcement
Officials

When are
prescribers
How often is it required to
updated
consult

Weekly

New patients
only

Practicioners,
Pharmacists,
Law
Enforcement
Officials

Monthly

Each time a
controlled
substance is
being prescribed

Practicioners,
Pharmacists

Once a week,
daily
submissions
are encouraged

Each time a
controlled
substance is
being prescribed

What drugs
are
monitored

Types of
Pharmacies
required to
consult

Schedule IIV

Community,
hospital
outpatient and
clinical
pharmacies, out
of state mail
order pharmacies

Schedule IIIII

Retail,
Institutional
(outpatient) and
Non-resident
pharmacies (mail
order)

Schedule IIV

Retail and
hospital

(Figure 1 – MA prescription monitoring program compared to RI and CT)

According to Gugelmann and Perrone (2011) with no set standard for all prescription
monitoring programs the result is inaccuracy and error within the systems. Perrone and Nelson
(2012) go on to state that variations in data collection from state to state limits the effectiveness
of the monitoring systems. Gugelmann and Perrone (2011) state that despite efforts from the
United States Bureau of Justice to use federal funds to support interstate access, the success of
prescription monitoring programs continues to be limited by variability in access across the
states. Some states allow for prescribers, pharmacists and special law enforcement whereas other
states only allow special law enforcement authorities to access the information in the database

A CASE STUDY OF THE REGULATIONS IMPOSED UPON MA
19
(Gugelmann and Perrone, 2011). Brushwood (2003) claims that without a unified system it is
impossible for prescription monitoring programs to function as intended. In addition, Clark et al.
(2012) state that an ideal prescription drug monitoring program would have standardized,
continuous access that meets the needs of the user.
Interstate collaboration and the creation of a national standard regarding informationsharing is essential. For example, Perrone and Nelson (2012) state that in urban areas that abut
state borders, interstate access is crucial in reducing diversion. Reisman et al. (2009) support this
claim by stating that interstate access allows for easier identification of doctor shoppers who
cross state lines to fraudulently obtain controlled substances in two different states. Paulozzi et
al. (2011), state that some prescription monitoring programs grant pharmacists the ability to
capture a unique serial number that is associated with each prescription. The serial number can
then be tracked to help identify duplicate prescriptions or stolen forms submitted at other
pharmacies. If this type of access were granted to pharmacists nationwide, it would be much
more difficult for drug seekers to doctor shop across state lines.
In addition to granting standardized, user-friendly access to pertinent stakeholders
nationwide it is important that the application process is not cumbersome. According to
Gugelmann and Perrone (2011) proper access to a patient’s full prescription history allows for
more informed prescribing on the part of the physician, and therefore less diversion and opioid
abuse. Informed prescribing not only allows for less diversion and abuse, but it also promotes
healthy and appropriate treatment of pain. Perrone and Nelson (2012) go on to state that in
addition to granting access, states should focus their attention on making the log-in and
application process simple and user-friendly. Having simple and user-friendly processes to gain
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access to the database would allow for a less cumbersome and frustrating experience, and
encourage more consistent usage.
Research Methodology
Overview
Drug abuse and misuse is a complex social issue that requires sensitivity within the
research method in conjunction with in depth analysis. Overall, the goal of this study was to
determine how different stakeholder groups feel regarding the effectiveness of the recent
regulations imposed upon the state’s prescription monitoring program. In particular this study
examined how stakeholders feel regarding the overall success of prescription monitoring
programs in general as well as gauge their perspectives on the effectiveness of the regulations in
terms of helping to combat drug abuse and misuse within the Commonwealth.
For this case study two methods of qualitative data collection were utilized: 1) in depth
interviews and 2) a survey. In addition the study targeted five key stakeholder groups including
the following: 1) legislators who served on the OxyContin and Heroin Commission in
Massachusetts, 2) both hospital and retail pharmacists who have experience with prescription
monitoring programs, 3) doctors and organizational representatives who have experience and/or
knowledge of opioid prescribing, 4) a sampling of recovering opioid addicts and, 5) substance
abuse counselors. Perspectives from all five of these stakeholder groups helped to determine
reoccurring themes in addition to any gaps in how different stakeholders view the effectiveness
of the recent regulations. This study also provided insight as to how the stakeholders feel
regarding the success of prescription monitoring programs in general.
Research Method
The research method was based on qualitative data that was generated through a single
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case study approach consisting of five subjects of analysis within the state of Massachusetts.
This study was based on a convenience sample and all subjects were contacted by email or via
the phone. Participants from all five stakeholder groups were asked to contribute on a voluntary
basis with no financial incentive. Data collection was conducted through a series of face-to-face
or phone interviews and surveys. The subjects of the interviews and participants of the surveys
were required to give informed consent prior to data collection. The letter of informed consent
for all participants can be viewed in Appendix H. The identity of all research participants
remained confidential throughout the entire process, and data will be destroyed when the study is
complete. All interviews were recorded, and transcribed. The data was analyzed through a
comparative process to determine any reoccurring themes or inconsistencies between the
stakeholders.
Interviews
In depth interviews were conducted face to face or over the phone with subjects from
four of the five stakeholder groups. One of the targeted groups consisted of a sample size of two
members from the Massachusetts State Legislature who have experience with the subject matter.
This particular study targeted legislators that served on the Massachusetts OxyContin and Heroin
Commission. The OxyContin and Heroin Commission was established in the 2007-2008
Legislative Session to study the growing opioid abuse epidemic in Massachusetts. As stated
earlier, the Commission released a report with findings on the subject and recommendations on
how the state should proceed in handling the growing epidemic.
The legislators were asked a series of questions pertaining to their contributions to the
Commission, their knowledge of opioid abuse and misuse prior to being on the Commission, the
current regulations surrounding the states prescription monitoring program, the recommendations
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that were made by the Commission and how they feel regarding the effectiveness of those
recommendations at this time. The interview questions for legislators are outlined in Appendix
C. Face to face or phone interviews were selected for this group because legislators may be able
to offer additional information regarding their experience or knowledge of the subject outside of
the interview questions that may add to the research. Subjects for this group will be recruited and
contacted through their official capacity at the Massachusetts State House, or if they have since
left the legislature through their current profession.
The second stakeholder group that was targeted is pharmacists. In order to gain a broad
perspective both hospital and retail pharmacists were targeted. This study focused on a sample
size of nine pharmacists that either had experience with prescription monitoring programs in
Massachusetts, prescribing opioids themselves or were knowledgeable in prescribing opioids in
general. The Prescription Monitoring Program used in Massachusetts is online and is a secure
website that supports safe prescribing and dispensing. Massachusetts’s regulations now require
pharmacies to use the Online Prescription Monitoring Program, which exposes the majority of
pharmacists in Massachusetts to the recent regulations.
The pharmacists were asked a series of questions regarding their experience using the
prescription drug monitoring program, their views on the effectiveness of the recent regulations
surrounding prescription monitoring programs, how they feel regarding the effectiveness of the
regulations in terms of helping to combat drug misuse and abuse, and their views on over and
under prescribing by doctors. The interview questions for pharmacists are outlined in Appendix
D. Face to face and phone interviews were conducted with this group because as professionals
they may be able to offer additional pertinent information relating to the subject matter that is not
covered in the interview questions. Subjects for this group were recruited and contacted through
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their official capacity at either local retail pharmacies or through local pharmaceutical hospital
contacts.
The third stakeholder group that was targeted is doctors. In order to gain a broad
perspective both physicians and organizational representatives were targeted. The sample of four
doctors with experience prescribing pain medication brought a unique perspective due to the fact
that the recent regulations have changed the way in which their industry operates. This study
targeted physicians that treat chronic pain because they had experience prescribing opioids
themselves. The doctors were asked a series of questions regarding how the regulations have
affected their ability to do their job, their thoughts surrounding misuse and abuse of opioids in
general, their views on under and over prescribing in general, and how they feel regarding the
effectiveness of the regulations surrounding prescription monitoring programs in terms of
helping to combat drug misuse and abuse. The interview questions for doctors are outlined in
Appendix E. This stakeholder group was interviewed face to face or over the phone because the
doctors may be able to offer additional information or insight not covered within the questions
based on their personal and professional experience. Subjects for this group were recruited and
contacted through the states medical association.
The fourth stakeholder group that was interviewed face to face or over the phone for data
collection is substance abuse counselors. In addition to surveying recovering opioid addicts,
substance abuse counselors were targeted in order to gain a broader perspective. The sample size
of this group consisted of two people. The substance abuse counselors were asked a series of
questions regarding how their patients are most commonly introduced to opioid drug, how they
most commonly become addicted and how they most commonly obtain the drugs on a regular
basis. This data provided insight on how and why prescription drugs are most frequently
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misused, abused and/or making their way to street in Massachusetts. Lastly, they were asked a
series of questions regarding the recent regulations surrounding prescription monitoring
programs, and their views on the effectiveness of such regulations. The interview questions for
recovering substance abuse counselors are outlined in Appendix F. For this stakeholder group
face to face or over the phone interviews were conducted because they may be able to offer
additional information or insight not covered within the questions based on their personal and
professional experience. Subjects for this group will be recruited and contacted through their
official capacity.
Surveys
The fifth stakeholder group that will be targeted for data collection is recovering opioid
addicts. The sample size will be eight individuals and the identity of participants who fill out the
surveys will be kept anonymous for confidentiality purposes. This stakeholder group will
provide an important perspective because these are the people who have experience with
addiction, and know how the drugs are commonly being misused and abused from personal
experience. The survey will ask a series of questions regarding how the participant was
introduced to the drug, how they became addicted and how they obtained the drugs on a regular
basis. This data will provide insight on how and why prescription drugs are most frequently
misused, abused and/or making their way to street in Massachusetts. Lastly, they will be asked a
series of questions regarding recent regulations surrounding prescription monitoring programs,
and their views on the effectiveness of such regulations. The survey questions for recovering
addicts are outlined in Appendix G. For this stakeholder group a survey is being conducted
because of the sensitive nature of the questions being asked. The participants may not feel
comfortable sharing such personal details in a face to face setting. Subjects for this group will be
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recruited and contacted through local substance abuse counselors.
Results/Findings
Overview
Significant data was collected from a variety of sources within all five stakeholder
groups: 1) legislators, 2) both hospital and retail pharmacists who have experience with
prescription monitoring programs, 3) doctors and organizational representatives who have
experience and/or knowledge of opioid prescribing, 4) substance abuse counselors and 5) a
sampling of recovering opioid addicts. Face to face or phone interviews as well as a series of
surveys yielded data from two legislators, nine pharmacists, three doctors, one medical
organizational representative, two substance abuse counselors and eight recovering addicts. Two
main themes were established throughout the interviews and surveys which are as follows: 1)
stakeholders in Massachusetts believe prescription monitoring programs are successful in
combating prescription drug abuse and/or misuse and, 2) stakeholders in Massachusetts have an
overwhelmingly negative attitude towards Massachusetts program design.
Prescription Monitoring Programs are Successful
A large number of the subjects believed that prescription monitoring programs are (or
have the potential to be) successful in combating prescription drug abuse and/or misuse. Both
legislators stated that they believe prescription monitoring programs are a successful way to
combat prescription drug abuse and/or misuse. One in particular claimed that “Prescription
monitoring programs are one of the ways we can help reduce prescription drug abuse. We all
know that these drugs need to be prescribed by a licensed physician. Drug monitoring programs
allows us to track who and more importantly how many prescriptions are being prescribed.” The
other subject went on to state that “prescription monitoring programs can help us find legitimate
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versus illegitimate prescribers.” That same subject then stressed the need for proper program
design when developing a prescription monitoring program, “I believe prescription monitoring
programs have the potential to be successful, if implemented properly.”
All of the pharmacists responded positively when asked if they believed prescription
monitoring programs are successful in combating prescription drug abuse and/or misuse. One
subject responded with “Yes!” while another stated “Yes, I believe prescription monitoring
programs help reduce abuse and misuse of drugs.” Another subject went on to state “They are
definitely helpful. I have seen it! I’ve had doctors call and tell us to cancel refills on a controlled
substance since the patient was identified on PMP.” Lastly, one of the pharmacist subjects stated
that “prescription monitoring programs are definitely helpful, but still relatively new. I think as
more time passes and it becomes more used by RPh (Registered Pharmacist)/ MD (Doctor of
Medicine) it will help to actually curb the misuse of prescription drugs.”
Half of the doctors that were interviewed felt as though prescription monitoring programs
are successful in combating prescription drug abuse and/or misuse. One subject stated that “I
think they can and potentially will be successful, baring implementation.” While another one of
the doctors stated “Yes, they are successful. However, the way in which prescription monitoring
programs are run could be improved. A centralized database that crossed state lines would be
better.”
The substance abuse counselors that were interviewed vastly believed that prescription
monitoring programs are successful in combating prescription drug abuse and/or misuse. One
subject stated “Absolutely, I have already seen it in action. Patients in treatment who were
receiving prescriptions that we weren’t aware of, we are now aware of. More importantly, it
opens a discussion between patients and their physicians.” The other subject said “I love the
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PMP. I see a lot of patients from New Hampshire that do not have one and there is a clear
difference – it is scary. We should consider adding Suboxone and methadone to the database that
would greatly benefit substance abuse counselors.”
The recovering addicts that were surveyed were not familiar with prescription monitoring
programs.
Negative Attitude / Lack of Knowledge
Throughout the interviews and surveys an overwhelmingly negative attitude and general
lack of knowledge surrounding Massachusetts’s prescription monitoring program emerged from
many of the stakeholders, which was surprising given that most of the stakeholders felt as though
prescription monitoring programs are successful. One of the legislators stated that “The
recommendations of the commission for the states prescription monitoring program were
positive, but Massachusetts is nowhere near meeting those goals.” That same subject went on to
state the Department of Public Health needs to find more innovative ways to improve
Massachusetts’ prescription monitoring program, “If the Department of Revenue can track
parking tickets in real time, why can’t the Department of Public Health find a way to track this
data real time.” The other legislator stated “More needs to be done in strengthening the states’
program. More collaboration needs to exist among federal and state officials.”
The pharmacists also portrayed a negative attitude and general lack of understanding.
One subject stated “Massachusetts program could be effective if we put serious resources
towards making it better.” Whereas another subject stated “I believe it has helped to some extent,
but much more work needs to be done.” Another subject went on to say “I can check the
prescription monitoring program, but what do you want me to do with that info? Electronic
system is better than the old way; however, I have no idea who is even tracking the information.”
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In addition, one subject stated “the database is not checked very often, there is a lag in real time
information. Sometimes the information is not available when you need it, and then you find out
later on that someone was doctor shopping when both pharmacies have a chance to upload the
information.”
The doctors that were interviewed were extremely negative towards Massachusetts
program design as a result of the regulations. One subject stated “The regulations were poorly
drafted and would waste a lot of physicians time in looking up all new patients, regardless of any
relationship to opioids much less a risk of abuse.” Another subject stated “Research should be
done to pinpoint the connection between opioid abuse and prescribing. Research from the top
down and interventions in identified areas of abuse will be more effective than mandating all
practitioners to follow the dictates of the DPH.” Another subject stated “No, I don’t think the
regulations will help in reducing abuse. Until doctors have more latitude to provide care to
patients, have enough time to spend with them and are able to prescribe alternatives to narcotics
it will be hard to do this justice.” In addition, one subject said “This is a multifactorial problem
and like most things regulations look for easy unidirectional answers – those generally make
things harder for the conscientious and don’t slow down the ones of concern. I wish they would
talk to primary care doctors in practice and find out what the issues are and address those!”
One of the substance abuse counselors stated that “Massachusetts PMP can be
cumbersome; having a delegate would be helpful.” In addition, one of the subjects was not
familiar with the regulations at all “I am not familiar with the regulations, but all healthcare
workers should know what other meds are being prescribed by other providers, and be vigilant
about contradictions.”
Other
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There were various findings throughout the case study that were not shared broadly
across the group yet they were still noteworthy. One of the legislators stated “If the
Commonwealth placed more resources in educating and rehabilitating those with drug issues, I
truly believe there will be a reduction in overall crime and more importantly, a reduction in
overdoses.” One of the pharmacists stated that “regulating the industry has potentially made it
more dangerous for patients. Prescription opioids are a gateway to addiction and when patients
are addicted and cannot access these medications (or don’t have the support to break their
addiction) they turn to more dangerous street drugs like heroin.” However, one of the doctors
stated “Prescriptions are issued for the primary purpose of treating patients appropriately; we
must not lose sight of this in a rush to respond to the established addiction and overdose
problems in our society. Licensing boards have the clinical expertise to balance patient needs
with proper practitioner standards of care. The DPH does not have broad based expertise in this
area.”
Both the substance abuse counselors and the recovering opioid addicts felt as though
people will continue to find the drugs no matter what types of regulations are put into place. One
of the substance abuse counselors stated “As long as drugs are good and kill pain, people will
want them. There are so many levels of issues to cover that I don’t know that any amount of
legislation can cover them all and actually be effective.” In addition, when asked whether they
believed regulating the prescription drug industry has helped to combat drug abuse all of the
recovering addicts said no. One subject in particular stated “I don’t think it has had any effect.
Making them harder to get doesn’t mean they cannot be found.” Another subject stated “I think
they ought to help the addict, not make him/her turn to crime to get the drugs.” The perspectives
of the recovering addicts is important and will be discussed in the paragraphs below.
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Discussion
The findings of this case study yielded very positive results in terms of how the
stakeholders view the effectiveness of prescription monitoring programs in general. Majority of
the stakeholders displayed positive feelings regarding the usefulness of prescription monitoring
programs in conjunction with stressing the need for proper program design. However, there was
an overwhelmingly negative attitude towards Massachusetts program design and a general lack
of knowledge surrounding the prescription monitoring program itself. Subjects raised concerns
ranging from real time data issues, the need for federal and state collaboration, interstate access
and cumbersome and time consuming processes.
The findings of this study are interesting because with the help of recent regulations, the
Massachusetts’s prescription monitoring program design meets most of the technical components
of an ideal prescription monitoring program. The program uses an electronic data transmission
system, it has real time data capabilities and it is comprehensive and accurate. However,
Massachusetts does not share data across state lines and there are no nationwide standards for
who has access to the database.
Many complaints were lodged regarding real time data. One legislator questioned why
the Department of Public Health has not come up with a way to track this information live.
However, the capability to access real time information is there. It is not an issue regarding the
technical components but rather an issue of physical resources. In order to have the information
readily available pharmacists would have to be updating the database simultaneously as they
were dispensing the drugs. A disadvantage to placing a requirement such as this on the
pharmacists is that it would be extremely time consuming and an unrealistic expectation. In
addition, some may argue that this type of pressure and added responsibility could potentially
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affect the quality of service provided by the pharmacists.
Many of the stakeholders also claimed that more federal and state collaboration is
needed. Federal and state collaboration would allow for interstate sharing and push the federal
government to set a national standard for who has access to the database. Standardized access
would allow for more comprehensive interstate sharing and increase the amount of information
available to those who have access to the database. One may conclude that interstate sharing
would be particularly beneficial to those practicing close to the border of neighboring states.
Interstate sharing in Massachusetts would close the gap in terms of what Massachusetts’s
prescription monitoring program design is lacking.
Several of the stakeholders, including those who are expected to use the program on a
regular basis, displayed a general lack of knowledge regarding the state’s prescription
monitoring program and the recent regulations surrounding the program. Many of the
stakeholders were simply unaware of how the program was designed and how it is intended to
function. The recent regulations allow for the creation of delegates to act on behalf of registered
participants, and the OxyContin and Heroin Commission did consult with primary care
physicians across the Commonwealth when drafting recommendations. The fact that some of the
stakeholders were unaware of the provisions surrounding delegates and did not realize that the
commission consulted with primary care physicians prior to making recommendations shows a
lack of communication between the stakeholders and the policy makers. In addition, the fact that
some of the pharmacists were unclear as to what happens with the information once they report it
is an area that needs improvement.
It is important to note that a few of the stakeholders provided insight that was not
consistent amongst all stakeholders, but was still pertinent to the overall discussion. One of the
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legislators very adamantly stated that the opioid epidemic is a multilateral issue which warrants a
comprehensive approach in terms of combating the overall problem. This statement was
corroborated by one of the doctors who claimed that regulating the industry could potentially
make it more dangerous for addicts or push them to turn to street drugs such as heroin. In
addition, one of the recovering opioid addicts stated that policy makers should be helping the
addict instead of forcing him or her to crime. All of these statements warrant the consideration
of policy makers regarding how the state is investing in rehabilitation services and what kind of
access is available to those who are in need. This case study suggests that in addition to
maintaining a fully functional prescription monitoring program a deeper look at the overall
services available to addicts is necessary in order to truly combat opioid abuse and/or misuse
within the Commonwealth.
Recommendations
Definitive statements regarding further policy recommendations cannot be made at the
conclusion of this case study. However, the research does suggest that further study is warranted
and a different approach in terms of program design is desired. The first recommendation is to
determine how widespread the negative attitude and general lack of knowledge regarding the
states prescription monitoring program truly is. Policy makers should be charged with organizing
a commission, much like the OxyContin and Heroin Commission, to investigate and determine
the attitudes and knowledge of stakeholders across the Commonwealth. This Commission should
hold forums across the Commonwealth in order to gain insight as to how widespread the
negative feelings and lack of knowledge is felt amongst stakeholders in Massachusetts. Insight
from a larger sample of stakeholders will help to determine if further study and recommendations
are needed.
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The second recommendation is for policy makers and the Department of Public Health to
develop a campaign to educate users on the benefits of the program, how the program is intended
to function and to encourage routine use. For example, doctors should be encouraged to consult
the database every time they prescribe a controlled substance, not just for new patients. In
addition, pharmacists should be encouraged to update the database in a timely manner in order to
help curb doctor shopping and diversion. If policy makers and the Department of Public Health
want to restore faith in the Massachusetts’s prescription monitoring program they must educate
the primary users on the benefits of such behaviors. In addition, it would be helpful to outline
how Massachusetts program compares to other programs nationwide to give stakeholders a better
sense of how Massachusetts is performing on a larger scale.
The third recommendation is for policy makers and the Department of Public Health to
engage the state’s licensing board. It is imperative that the pharmacists and physicians
understand how the licensing board fits within the overall process and are educated on their
procedures. These particular stakeholders should feel confident that any pertinent information
that is funneled into the database is making its way to the licensing board when necessary.
According to this case study, many stakeholders do not feel confident that the information they
are submitting is making its way to the correct authorities. If the primary users of the system do
not have faith in the overall purpose of the program it is inevitable that they will not regularly
use the program.
Limitations
There were a few limitations encountered throughout this case study. The main limitation
was a condensed amount of time for research, in addition to the scope of research evolving over
time. There were only two months in between IRB approval and the date of completion. This
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time frame limited the amount of data collection for such a complex and wide ranging issue. In
addition, it was somewhat difficult to get professionals to agree to be interviewed because of the
sensitive nature of the topic and the fact that opioid abuse is an emerging issue in the
Commonwealth at this time. Many potential participants were hesitant to open up about the issue
in fear of jeopardizing their career by providing information they were not authorized to provide.
In addition, the Department of Public Health was unwilling to communicate or give any
perspective on the issue stating that the regulations were still a work in progress and they were
not at liberty to discuss them.
Conclusion
After extensive research and literature review, this case study revealed that further study
and action on behalf of the policy makers and Department of Public Health is needed at this time.
The research question was proposed as follows: do major stakeholders see the recent regulations
imposed upon the states prescription monitoring program as being effective in helping to combat
abuse and misuse of prescription opioids in Massachusetts? According to this case study the
answer is inconclusive at this time. However, despite the fact that definitive statements regarding
the larger population of stakeholders cannot be made, the study does suggest that although
stakeholders in Massachusetts believe prescription monitoring programs are successful in
combating prescription abuse and/or misuse they have a predominantly negative outlook
regarding the program design of Massachusetts program in particular with regards to the recent
regulations imposed upon the program. Although Massachusetts’s prescription monitoring
program appears to meet the technical components of a successful prescription monitoring
program many of the pertinent stakeholders lack general knowledge on how the program is
intended to function, are frustrated with the usability of the program and do not have faith in the
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overall outcome.
Due to the fact that prescription monitoring programs are still relatively new, additional
research and assessment of different programs across the country is necessary in order to truly
define the ideal prescription monitoring program. However, Massachusetts can make more of an
impact in terms of combating prescription opioid abuse and misuse by encouraging routine use
and educating users in order to garner additional support of the program. In addition to
maintaining a useful prescription monitoring program policy makers and other governmental
authorities must commit to supporting other initiatives surrounding substance abuse in order to
achieve the overall goal of decelerating the opioid epidemic in Massachusetts. On March 27 of
this year Governor Deval Patrick stated that he would commit $20 million in additional funds to
increase drug treatment and recovery services (State House News Service, 2014). This is a step
in the right direction, however, a more detailed and extensive plan is needed in the near future.
The legislature must act, and they must act fast in order to truly have an impact in terms of
combating the overarching issue.
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Appendix C
1) How long have you been a member of the Massachusetts state legislature?
2) How did you become a member of the OxyContin and Heroin Commission?
3) Prior to being on the Commission what were your thoughts on prescription opioid
abuse being a problem in MA? Did that change throughout the process of being on
the Commission? How so?
4) Are you familiar with how prescription monitoring programs? If yes, can you
elaborate on how they are intended to function as a result of the recommendations of
the commission?
5) Do you feel that prescription monitoring programs are successful in combating
prescription drug abuse?
6) Do you personally believe that over-prescribing and/or under-prescribing is an issue
in MA? If yes to either, can you elaborate on how so?
7) Is there anything you think the Commonwealth should be doing in order to combat
prescription drug abuse that we are not doing?
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Appendix D
1) How long have you been working within the pharmaceutical industry?
2) Are you licensed to dispense drugs containing opioids?
3) Are you familiar with the recent regulations imposed upon the states prescription drug
monitoring program? If yes, can you elaborate on them?
4) Can you explain how prescription monitoring programs work?
5) In your professional opinion, do you believe prescription monitoring programs are
successful in reducing abuse and misuse of prescription drugs?
6) Do you believe that a doctor over-prescribing and/or under-prescribing is an issue in
MA? If yes to either, can you elaborate on how so?
7) In your opinion, do you believe that regulating the states prescription drug monitoring
program has helped combat drug abuse in MA?
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Appendix E
1) How long have you been working within the medical industry?
2) Are you licensed to prescribe drugs containing opioids?
3) How effective do you think opioids are in terms of treating pain? Do you believe they
are highly addictive? If so, does that affect your willingness to prescribe them?
4) Are you familiar with the recent regulations imposed upon the states prescription
monitoring program?
5) If yes, can you describe how the regulations have affected you doing your job?
6) In your professional opinion, do you believe that prescription monitoring programs
are successful in reducing abuse and misuse of prescription drugs?
7) Do you believe that a doctor over-prescribing and/or under-prescribing is an issue in
MA? If yes to either, can you elaborate on how so?
8) In your opinion, do you believe that regulating the states prescription drug monitoring
program has helped combat drug abuse in MA?
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Appendix F
1) How long have you been working as a substance abuse counselor?
2) Do you treat patients who are abusing and/or misusing drugs containing opioids?
3) How effective do you think opioids are in terms of treating pain? Do you believe they are
highly addictive?
4) Where do majority of the patients you see obtain the opioids they abuse and/or misuse?
5) Do you believe that a doctor over-prescribing and/or under-prescribing is an issue in
MA? If yes to either, can you elaborate on how so?
6) Are you familiar with the recent regulations imposed upon the states prescription
monitoring program?
7) Do you believe that prescription monitoring programs are successful in reducing abuse
and misuse of prescription drugs?
8) In your opinion, do you believe that regulating states prescription monitoring programs
has helped to combat drug abuse in MA?
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Appendix G
1) How long has it been since you stopped using prescription drugs?
___0-12 months
___Between 1 and 4 years
___Between 4 years and 5 years
___More than 5 years
2) How did you become addicted to narcotics? (short answer below)

3) Are you familiar with the regulations imposed upon the prescription drug industry?
___yes ___no ___not sure
4) When you were using where did you most often get the narcotics?
___a friend
___prescription from my doctor
___prescription drug dealer
___other
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5) Have you ever relapsed?
___yes ___no
6) If yes, why triggered the relapse? (short answer below)

7) In your experience, where do you feel most addicts get their narcotics? (short answer below)

8) Do you believe that regulating the prescription drug industry (ie. instituting stricter laws for
prescription monitoring programs, and harsher penalties for doctors that over-prescribe) has
helped combat drug abuse? Please explain.
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Appendix H
XXXX, 2014
Dear Prospective Participant,
My name is Meredith Rodman and I am a graduate student at the University of
Massachusetts Boston in the Department of Public Policy and Public Affairs. I am conducting a
research project examining the regulations imposed upon the prescription drug industry within
Massachusetts as they relate to prescription monitoring programs. As a scholar in this field, I am
hoping to interview you in person or over the phone, for about 30 to 60 minutes.
After I complete all of my interviews, I plan to write up the results of my study. Any
information I use from the interviews would be presented in such a way as to ensure
confidentiality. You could end the interview or not answer questions at any point for any reason.
While I cannot promise any direct benefit from your participation in this study, I hope that it will
provide systematically collected data on what scholars in the field of prescription drug
regulations see as emerging issues. I would be pleased to provide you with a copy of what I
write.
University research procedures govern this project and I would be pleased to answer
questions about these procedures at any time. This project has been reviewed by the Institutional
Review Board at the University of Massachusetts Boston. Approval of this project only signifies
that the procedures adequately protect the rights and welfare of participants. Should you have
any questions or concerns for the Institutional Review Board (IRB), you may contact IRB
directly at the Office of Research Compliance at (617) 287-5374 or at human.subjects@umb.edu.
I hope to speak with you about emerging issues in the field of prescription drug regulations. If
you are willing to talk with me, just let me know and I will contact you to set up a time.
Thank you,
Meredith Rodman
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